Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024
05 déc. 2024 10h36 HE
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive analysis of the...
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
23 sept. 2024 09h50 HE
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient,...
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
13 août 2024 16h05 HE
|
Dyadic International, Inc.
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint...
Global Plasma Derived Therapies Market to Surpass US$58 Billion by 2028 with Robust Growth in Immunoglobulin and Albumin Segments
11 juin 2024 09h14 HE
|
Research and Markets
Dublin, June 11, 2024 (GLOBE NEWSWIRE) -- The "Plasma Derived Therapies Market (Immunoglobulin, Hemophilia, Specialty, and Albumin): Insights & Forecast (2024-2028)" report has been added to ...
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
30 avr. 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic to Attend Industry Events in April
27 mars 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
14 mars 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building...
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11 mars 2024 09h57 HE
|
Dyadic International, Inc.
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11 mars 2024 08h30 HE
|
Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Plasma Fractionation Market to reach USD 42.6 billion by 2031, Expanding at a CAGR of 6.7%: Transparency Market Research, Inc.
06 mars 2024 08h00 HE
|
Transparency Market Research
Wilmington, Delaware, United States, March 06, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global plasma fractionation market is estimated to flourish at a CAGR of 6.7% from...